Terns’ NASH drug meets primary, secondary endpoints in PhIIa trial

Terns Pharmaceuticals said a high dose of its experimental oral NASH treatment helped reduce liver fat in a Phase IIa trial.

The Foster City, CA-based biopharma said Tuesday in a release that TERN-501, a once-a-day THR-β agonist, met the primary endpoint and all secondary endpoints in…
Click here to view original post